logo
Sign in

ACAD Stock Price, Chart, Stats & News

ACADIA Pharmaceuticals Inc.
Save
4.00B
Market cap
11.45x
Current P/E
65.36x
Forward P/E

ACAD chart

1M
3M
1Y
5Y
Loading chart...

Fundamentals

Gross margin
91.69%
Operating margin
9.78%
Pretax margin
12.96%
Net margin
36.49%
Effective tax rate
-181.49%
ROA
25.00%
ROE
41.90%
D/E
0.04x
Interest coverage ratio

ACAD valuation

P/E
11.45x
P/S
3.30x
P/B
2.86x
P/CF
31.99x
P/FCF
33.65x
P/OCF
31.99x
PEG
0.19x
EV multiple
27.88x

About

ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis.

Similar securities

Based on sector and market capitalization

Report issue